Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 14
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Torquetenovirus Loads in Peripheral Blood Predict Both the Humoral and Cell-Mediated Responses to SARS-CoV-2 Elicited by the mRNA Vaccine in Liver Transplant Recipients.
Minosse C, Matusali G, Meschi S, Grassi G, Francalancia M, D'Offizi G, Spezia PG, Garbuglia AR, Montalbano M, Focosi D, Girardi E, Vaia F, Ettorre GM, Maggi F. Minosse C, et al. Among authors: francalancia m. Vaccines (Basel). 2023 Oct 28;11(11):1656. doi: 10.3390/vaccines11111656. Vaccines (Basel). 2023. PMID: 38005988 Free PMC article.
Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination.
Matusali G, Petruccioli E, Cimini E, Colavita F, Bettini A, Tartaglia E, Sbarra S, Meschi S, Lapa D, Francalancia M, Bordi L, Mazzotta V, Coen S, Mizzoni K, Beccacece A, Nicastri E, Pierelli L, Antinori A, Girardi E, Vaia F, Sette A, Grifoni A, Goletti D, Puro V, Maggi F. Matusali G, et al. Among authors: francalancia m. Vaccines (Basel). 2023 Sep 28;11(10):1541. doi: 10.3390/vaccines11101541. Vaccines (Basel). 2023. PMID: 37896943 Free PMC article.
Third dose of SARS-CoV2 mRNA vaccination produces robust persistent cellular and humoral immune responses in liver transplant recipients.
Montalbano M, Piccolo P, Lionetti R, Visco-Comandini U, Agrati C, Grassi G, Meschi S, Matusali G, Conte F, Angelone F, Ettorre GM, Guglielmo N, Maggi F, Francalancia M, Mereu T, Puro V, Girardi E, D'Offizi G. Montalbano M, et al. Among authors: francalancia m. Liver Int. 2023 May;43(5):1120-1125. doi: 10.1111/liv.15557. Epub 2023 Apr 1. Liver Int. 2023. PMID: 36929682
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.
Rescigno M, Agrati C, Salvarani C, Giannarelli D, Costantini M, Mantovani A, Massafra R, Zinzani PL, Morrone A, Notari S, Matusali G, Pinter GL, Uccelli A, Ciliberto G, Baldanti F, Locatelli F, Silvestris N, Sinno V, Turola E, Lupo-Stanghellini MT, Apolone G; VAX4FRAIL study Group. Rescigno M, et al. Front Immunol. 2023 Jan 27;14:1104124. doi: 10.3389/fimmu.2023.1104124. eCollection 2023. Front Immunol. 2023. PMID: 36776853 Free PMC article.
External quality assessment of SARS-CoV-2 serology in European expert laboratories, April 2021.
Mögling R, Colavita F, Reimerink J, Melidou A, Leitmeyer K, Keramarou M, Lapa D, Francalancia M, Murk JL, Vossen A, Carletti F, Hogema B, Meijer A, Deprez L, di Caro A, Castilletti C, Reusken CB. Mögling R, et al. Among authors: francalancia m. Euro Surveill. 2022 Oct;27(42):2101057. doi: 10.2807/1560-7917.ES.2022.27.42.2101057. Euro Surveill. 2022. PMID: 36268736 Free PMC article.
Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
D'Apice L, Trovato M, Gramigna G, Colavita F, Francalancia M, Matusali G, Meschi S, Lapa D, Bettini A, Mizzoni K, Aurisicchio L, Di Caro A, Castilletti C, De Berardinis P. D'Apice L, et al. Among authors: francalancia m. Front Immunol. 2022 Sep 26;13:981693. doi: 10.3389/fimmu.2022.981693. eCollection 2022. Front Immunol. 2022. PMID: 36225911 Free PMC article.
Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results.
Agrati C, Castilletti C, Battella S, Cimini E, Matusali G, Sommella A, Sacchi A, Colavita F, Contino AM, Bordoni V, Meschi S, Gramigna G, Barra F, Grassi G, Bordi L, Lapa D, Notari S, Casetti R, Bettini A, Francalancia M, Ciufoli F, Vergori A, Vita S, Gentile M, Raggioli A, Plazzi MM, Bacchieri A, Nicastri E, Antinori A, Milleri S, Lanini S, Colloca S, Girardi E, Camerini R, Ippolito G, Vaia F, Folgori A, Capone S. Agrati C, et al. Among authors: francalancia m. NPJ Vaccines. 2022 Sep 24;7(1):111. doi: 10.1038/s41541-022-00531-8. NPJ Vaccines. 2022. PMID: 36153335 Free PMC article.
22 results